The *INS* (insulin), *CTLA-4* (polymorphic cytotoxic T-lymphocyte--associated antigen), and *PTPN22* (protein tyrosine phosphatase nonreceptor type 22) genes are some of the confirmed non-HLA genes associated with type 1 diabetes ([@B1][@B2][@B3]--[@B4]). The *INS* gene on chromosome 11p15 confers about 10% of the genetic susceptibility to type 1 diabetes; both a variable number of tandem repeats located ∼0.5 kb upstream of *INS* ([@B1]) and other polymorphisms in tight linkage disequilibrium (LD) such as −23HphI and +1140A/C ([@B5]) have been implicated as etiological factors. All of the polymorphisms lie outside coding sequences, suggesting that diabetes susceptibility derives from modulation of *INS* transcription ([@B6]).

The lymphoid-specific phosphatase (LYP), encoded by the *PTPN22* gene on chromosome 1p13, is involved in preventing spontaneous T-cell activation. The C1858T single nucleotide polymorphism (SNP) results in a missense mutation that changes an arginine at position 620 to a tryptophan and, thereby, abrogates the ability of the molecule to bind to the signaling molecule Csk (c-Src tyrosine kinase) ([@B3],[@B7],[@B8]). The Trp620 variant is associated with autoimmune disorders including Graves\' disease ([@B9]), rheumatoid arthritis ([@B7]), and systemic lupus erythematosus ([@B10]).

The *CTLA-4* gene on chromosome 2q33 encodes a molecule that functions as a negative regulator of T-cell activation. The G allele of the first exon (Ala17Thr) has been most consistently associated with type 1 diabetes ([@B11]) and reduced control of T-cell proliferation ([@B12]). The (AT)n microsatellite marker in the 3′ untranslated region, in strong LD with Ala17Thr, is also associated with type 1 diabetes ([@B2]) and Graves\' disease ([@B13]). In this study, we genotyped the children participating in the Diabetes Autoimmunity Study in the Young (DAISY) for polymorphisms in *INS*, *CTLA-4*, and *PTPN22* to explore how these genes influence development of persistent islet autoimmunity and progression from persistent islet autoimmunity to type 1 diabetes.

RESEARCH DESIGN AND METHODS
===========================

Since 1993, DAISY has followed two cohorts of young children at increased risk of type 1 diabetes: the siblings and offspring cohort (SOC) of relatives of type 1 diabetes patients and the general population newborn cohort (NEC). The latter consists of children expressing type 1 diabetes susceptibility HLA-DR,DQ genotypes identified through screening of over 31,000 newborns at St. Josephs Hospital, Denver, Colorado. The details of screening and follow-up have been previously published ([@B14]). Children in this cohort have been followed from birth to an average age of 7.0 years (range 5 months to 19.7 years). Informed consent was obtained from the parents of each study subject. The Colorado Multiple Institutional Review Board approved all study protocols.

Islet autoantibodies.
---------------------

Measurement of biochemical islet autoantibodies was performed in the laboratory of G.S.E. at the Barbara Davis Center. We used radioimmunoassays for autoantibodies to insulin, GAD65, and IA-2. The combined GAD65 autoantibody (GAA) and IA-2 autoantibody (ICA512AA) (or IA-2A) radioassay was done in duplicates on a 96-well filtration plate, and radioactivity was counted on a TopCount 96-well plate β-counter using methods previously described ([@B15]). The interassay coefficients of variation are 10 and 5% (*n* = 50) for GAA and ICA512AA, respectively. The upper limits of normal nondiabetic sera (0.032 for GAA, 0.049 for ICA512AA) were established as the 99th percentile of 198 healthy controls. In the 2005 Diabetes Autoantibody Standardization Program (DASP) workshop ([@B16]), the sensitivity and specificity were 76 and 99%, respectively, for GAA and 64 and 100%, respectively, for ICA512AA. Insulin autoantibodies were measured by a micro--insulin autoantibody (IAA) assay. An index was determined based on the difference in counts per minute between wells without and with cold insulin, with a positivity criterion of 0.010, which was the 99th percentile of 106 normal controls. The interassay coefficient of variation is 20% (*n* = 100) at low positive levels. In the 2005 DASP workshop, the sensitivity and specificity for micro-IAA were 58 and 99%, respectively.

Genotyping.
-----------

*INS*-23Hph1 (rs689), *CTLA-4* T17A (rs231775), and *PTPN22* R620W (rs2476601) polymorphisms were genotyped using a linear array (immobilized probe) method essentially as described in Mirel et al. ([@B17]). Briefly, ∼100 ng of genomic DNA was PCR amplified with biotinylated primers. The labeled amplicons were hybridized to an immobilized sequence-specific oligonucleotide probe (SSOP) array on a nylon membrane. The presence of bound amplicon to a specific probe is detected using streptavidin horseradish peroxidase and a soluble colorless substrate, tetramethylbenzidine, which can be converted in the presence of H~2~O~2~ to a blue precipitate.

Statistical analysis.
---------------------

All analyses were performed in SAS version 9.1. (SAS Institute, Cary, NC). The SNPs were in Hardy-Weinberg equilibrium for both affected and unaffected subjects. Ongoing recruitment since 1994 and continuing follow-up have resulted in variable lengths of follow-up, producing right-censored data. Some of the affected children were positive for autoantibodies on their first blood draw, producing left-censored data. Multiple imputation was used to generate time of autoantibodies status change for the left-censored subjects in order to perform an analysis on progression to type 1 diabetes. Two outcomes were analyzed, i.e., time to persistent islet autoimmunity and time from persistent islet autoimmunity to type 1 diabetes. A parametric model, accounting for right and left censoring assuming a Weibull distribution, was used, adjusting for presence of *HLA*-DR3/4,DQB1\*0302, ethnicity, sex, family history of type 1 diabetes, and age at detection of islet autoimmunity. Cumulative risk of development of persistent islet autoimmunity and progression from islet autoimmunity to type 1 diabetes by genotypes was estimated by survival analyses for each SNP. Follow-up time was defined as the age of the child at the first of the two consecutive positive visits for affected children and age of the child at the last visit for unaffected children. For the time to persistent islet autoimmunity, the survival curves were derived using Turnbull\'s algorithm, which is a nonparametric maximum likelihood estimator of survival function for arbitrarily truncated and censored data. For the time to type 1 diabetes from persistent islet autoimmunity, the Kaplan-Meier method was used to derive survival curves, which essentially approximates the interval-censored data. The Wilcoxon test was used to test differences in cumulative risk between groups. The analyses were based on genotypes using the additive model.

To determine whether inclusion of multiple siblings per family in this cohort affected our findings, we performed analyses treating siblings as correlated. As those results were the same, we are presenting the data treating siblings as independent. The level of significance was set at 0.05.

RESULTS
=======

Of the 2,449 children included in this analysis, 112 have developed persistent islet autoimmunity, i.e., one or more islet autoantibody (IAA, GAA, or IA-2A), in samples collected on two consecutive visits 3--6 months apart and positive at the last visit; 47 of these children have progressed to type 1 diabetes, defined by a random blood glucose measurement \>200 mg/dl and/or an A1C \>6.3% in the presence of diabetes symptoms.

Descriptive characteristics of the DAISY cohort are shown in [Table 1](#T1){ref-type="table"}. Affected (*n* = 112) compared with unaffected (*n* = 2,337) children were more likely to be non-Hispanic white, be positive for the *HLA*-DR3/4,DQB1\*0302 genotype, and have a first-degree relative (FDR) with type 1 diabetes. Allele frequencies of *PTPN22*, *INS*, and *CTLA4* SNPs are shown in [Table 2](#T2){ref-type="table"}. Affected subjects with persistent islet autoimmunity more often carried the risk alleles for *PTPN22* and *INS* with, respectively, unadjusted HR 1.81 (95% CI 1.26--2.59, *P* = 0.001) and 1.48 (1.06--2.06, *P* = 0.019).

###### 

Characteristics of the DAISY cohort

                                                                                        Affected with IA (*n* = 112)   Unaffected (*n* = 2,337)   Unadjusted HR (95% CI)   *P*
  ------------------------------------------------------------------------------------- ------------------------------ -------------------------- ------------------------ -------------
  [†](#TF1-2){ref-type="table-fn"}HLA-DR3/4 DQB1[\*](#TF1-1){ref-type="table-fn"}0302   47 (42.0)                      443 (19.0)                 **3.10 (2.13--4.51)**    **\<0.001**
  First-degree relative with type 1 diabetes                                            74 (66.1)                      1,004 (43.0)               **2.03 (1.37--3.00)**    **\<0.001**
  Sex (female)                                                                          62 (55.4)                      1,106 (47.3)               1.38 (0.95--2.00)        0.093
  [†](#TF1-2){ref-type="table-fn"}Non-Hispanic white                                    96 (85.7)                      1,667 (71.8)               **1.89 (1.11--3.21)**    **0.018**
  [‡](#TF1-3){ref-type="table-fn"}Follow-up time (years)                                4.85 ± 3.6                     7.11 ± 4.4                                          

Data are *n* (%) or means ± SD unless otherwise indicated. Please note that DAISY cohort is highly enriched in *HLA* DR3/4 DQB1\*0302 genotypes.

†*HLA* data missing for 4 children and ethnicity data missing for 16 children.

‡For affected, age of the child at the first of two consecutive positive visits; for unaffected, age of the child at the last visit. Boldface represents statistical significance.

###### 

Association of three SNPs with conversion to persistent islet autoimmunity and progression from persistent islet autoimmunity to type 1 diabetes

  Risk allele   Allele counts (freq.)   Univariate analyses   Conversion to persistent islet autoimmunity[\*](#TF2-1){ref-type="table-fn"} (112 cases/2,449 subjects in total)   Progression to type 1 diabetes[†](#TF2-2){ref-type="table-fn"} (47 cases/112 IA subjects)                                                               
  ------------- ----------------------- --------------------- ------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------- ----------------------- ----------- ----------------------- -----------
  PTPN22 (T)    37 (16.8)               452 (9.7)             **1.81 (1.26--2.59)**                                                                                              **0.001**                                                                                   **1.83 (1.27--2.63)**   **0.001**   0.98 (0.50--1.93)       0.962
  INS (A)       176 (78.6)              3,323 (71.8)          **1.48 (1.06--2.06)**                                                                                              **0.020**                                                                                   1.39 (0.99--1.95)       0.053       1.34 (0.72--2.52)       0.353
  CTLA4 (G)     95 (42.8)               1,850 (39.8)          1.11 (0.85--1.46)                                                                                                  0.429                                                                                       1.12 (0.86--1.46)       0.415       **0.54 (0.33--0.88)**   **0.014**

Data are *n* (%) unless otherwise indicated. \*Parametric model controlled for *HLA*-DR3/4,DQB1\*0302, ethnicity, sex, and first-degree relative with type 1 diabetes.

†Additionally controlled for age at onset of islet autoimmunity.

‡*PTPN22* (R620W) data missing for 5, *CTLA4* (T17A) for 14, and *INS*-23HphI for 23 children. Boldface represents statistical significance. IA, islet autoimmunity.

Cumulative incidence of the development of persistent islet autoimmunity and progression from islet autoimmunity to type 1 diabetes by genotypes for each SNP was estimated by survival analyses. The *PTPN22* (R620W) TT genotype was associated with a significantly (*P* = 0.002) higher incidence of persistent islet autoimmunity (27.3% by age 10 years) than the CT (7.9%) or CC (5.3%) genotype ([Fig. 1](#F1){ref-type="fig"}*A*). Cumulative incidence of progression to type 1 diabetes was also high in children with the *PTPN22* TT genotype, with three of four children progressing to type 1 diabetes. However, these results are not statistically significant, likely due to the small sample size ([Fig. 1](#F1){ref-type="fig"}*B*).

![Cumulative risk of development of persistent islet autoimmunity (calendar age) by *PTPN22* genotypes (*A*) and cumulative risk of progression from persistent islet autoimmunity to type 1 diabetes (follow-up time since first islet autoimmunity positivity) by *PTPN22* genotypes (*B*) were estimated by survival analyses.](zdb0040956920001){#F1}

Analysis stratified by the presence of the *HLA*-DR3/4,DQB1\*0302 genotype revealed the highest risk of islet autoimmunity in children carrying *HLA*-DR3/4,DQB1\*0302 and *PTPN22* TT genotypes (33.8% by the age of 10), although this is not statistically different from the risk in *HLA*-non**-**DR3/4,DQB1\*0302, *PTPN22* TT. The next highest risk genotypes were *HLA*-non**-**DR3/4,DQB1\*0302, *PTPN22* TT and *HLA*-DR3/4,DQB1\*0302, *PTPN22* CT, with the risks of islet autoimmunity by age 10 years being 25.0 and 24.8%, respectively ([Fig. 2](#F2){ref-type="fig"}*A*).

![*A*: Cumulative risk of development of persistent islet autoimmunity (calendar age) by *PTPN22* genotypes was estimated by survival analyses and stratified by high-risk *HLA*-DR3/4,DQB1\*0302. *B*: Cumulative risk of development of persistent islet autoimmunity (calendar age) by *INS* genotypes was estimated by survival analyses.](zdb0040956920002){#F2}

The *INS* genotype appeared to modulate slightly (*P* = 0.02) the cumulative incidence of persistent islet autoimmunity ([Fig. 2](#F2){ref-type="fig"}*B*). Within 10 years of detection of persistent islet autoimmunity, 7.8% of children with the *INS* AA genotype developed type 1 diabetes compared with 4.2 and 6.4% of those with AT and TT, respectively. There were no differences in the rate of progression from persistent islet autoimmunity to type 1 diabetes by the *INS*-23Hph1 genotypes (data not shown). Survival analyses of development of persistent islet autoimmunity and progression to type 1 diabetes showed no differences by *CTLA-4* genotypes (data not shown).

We further analyzed the associations of these three SNPs with development of persistent islet autoimmunity and progression from persistent islet autoimmunity to type 1 diabetes in a multivariate parametric model controlling for the presence of the *HLA*-DR3/4,DQB1\*0302 genotype, ethnicity, sex, family history of type 1 diabetes, and age at detection of islet autoimmunity ([Table 2](#T2){ref-type="table"}). The presence of the *PTPN22* T allele was a significant independent predictor of the development of persistent islet autoimmunity (HR 1.83 \[95% CI 1.27--2.63\], *P* = 0.001). However, the *PTPN22* T allele did not independently predict progression from islet autoimmunity to type 1 diabetes (0.98 \[0.50--1.93\], *P* = 0.96). The *INS* genotype did not independently predict islet autoimmunity or type 1 diabetes. The *CTLA-4* G allele, normally associated with type 1 diabetes risk, did not independently predict islet autoimmunity but was negatively associated with progression from islet autoimmunity to type 1 diabetes (0.54 \[0.33--0.88\], *P* = 0.01). There was no interaction between the effect of the *HLA*-DR3/4,DQB1\*0302 genotype and either *PTPN22, INS*, or *CTLA-4* genotypes for the risk of islet autoimmunity or type 1 diabetes (data not shown).

We also performed analyses by cohort, i.e., including 1,371 children from the NEC and 1,078 children from the SOC (supplemental Tables 1 and 2, available in an online appendix at <http://diabetes.diabetesjournals.org/cgi/content/full/db08-1179/DC1>). Affected NEC subjects with persistent islet autoimmunity more often carried the risk alleles for *INS* and *CTLA4* with, respectively, unadjusted HR 1.91 (95% CI 1.08--3.36, *P* = 0.03) and 1.58 (1.02--2.45, *P* = 0.04), whereas affected SOC subjects with persistent islet autoimmunity more often carried the risk allele for *PTPN22* with unadjusted HR 1.95 (1.27--3.00, *P* = 0.002). In a multivariate parametric model, the *PTPN22* T allele was associated with progression to persistent islet autoimmunity in SOC subjects (HR 2.17 \[95% CI 1.41--3.33\], *P* \< 0.001), whereas the *CTLA4* G allele was an independent predictor of the development of persistent islet autoimmunity in NEC subjects (1.57 \[1.01--2.44\], *P* = 0.046). The *CTLA-4* G allele, normally associated with type 1 diabetes risk, was negatively associated with progression from islet autoimmunity to type 1 diabetes in SOC subjects only (0.41 \[0.22--0.78\], *P* = 0.006). However, these results should be interpreted with caution due to the small sample size.

DISCUSSION
==========

Whereas the associations between the *INS*, *CTLA-4*, and *PTPN22* polymorphisms and type 1 diabetes are widely accepted, this study is the first comprehensive analysis of the effects of these genes on the age-specific incidence of persistent islet autoimmunity that precedes diagnosis of diabetes in all patients but may not necessarily lead to clinical diabetes. The distinction between the risk factors for islet autoimmunity versus type 1 diabetes is important because of potentially different mechanisms of gene-environment and gene-gene interaction in triggering islet autoimmunity versus epitope spreading and progressive loss of β-cell mass leading to overt diabetes. The results confirm the pivotal role of HLA-DR,DQ in both triggering islet autoimmunity and progression to type 1 diabetes. Whereas the *PTPN22* 1858 T allele may play a role at both stages leading to type 1 diabetes ([@B18]) and predict faster loss of the β-cell function afterward ([@B19]), in our population it appears to have an effect independent of the HLA-DR,DQ at the initial stage of islet autoimmunity development. *PTPN22* (R620W) results in a missense mutation that changes an arginine at position 620 to a tryptophan and, thereby, abrogates the ability of the molecule to bind to the signaling molecule Csk ([@B3],[@B20]). The LYP-Csk complex downregulates T-cell receptor signaling, and the diabetes-associated variant is reported to result in greater inhibition of T-cell receptor signaling ([@B8],[@B21],[@B22]). Consistent with an early and general effect on immune function is the finding that the minor tryptophan-encoding allele is associated with a series of autoimmune disorders including rheumatoid arthritis, systemic lupus erythematosus, Hashimoto thyroiditis, and Graves\' disease ([@B23],[@B7],[@B24]). Hermann et al. ([@B18]) showed evidence that *PTPN22* (R620W) regulates type 1 diabetes--specific autoimmunity and strongly affects the progression from preclinical to clinical diabetes in islet cell antibody--positive individuals.

Interestingly, when doing analyses separately by cohort, the *PTPN22* T allele is a strong independent predictor of the development of persistent islet autoimmunity in the SOC cohort, whereas the *CTLA-4* G allele is associated with progression to persistent islet autoimmunity in the NEC cohort. Different genetic loci influence the development of persistent islet autoimmunity and type 1 diabetes in individuals who have a family history of type 1 diabetes, and *PTPN22* seems to be one of the genetic factors responsible for increased type 1 diabetes risk in relatives of type 1 diabetic subjects.

The number of subjects carrying the *PTPN22* TT genotype is small, especially when analyzing progression from persistent islet autoimmunity to type 1 diabetes. Although three of four such children progress to type 1 diabetes, these results should be interpreted with caution due to the small sample size. This finding requires replication in independent populations.

Alternately, this study provides little support for a major independent effect of the *INS*(-23Hph1) or the *CTLA-4* (T17A) polymorphisms on triggering islet autoimmunity or progression to type 1 diabetes. The insulin gene has been consistently associated with type 1 diabetes in almost all the populations that have been tested, with an odds ratio (OR) between 2 and 3 ([@B1],[@B5]). We found a weak association of *INS* AA genotype with persistent islet autoimmunity, but not with progression to type 1 diabetes, after adjusting for the effect of the *HLA*-DR3/4,DQB1\*0302 genotype and demographic factors. The adjustment or smaller sample size may account for weaker than expected effect ([@B25],[@B26]). Although *INS* is a known factor associated with type 1 diabetes risk, its genetic effect seems to be rather weak overall and is therefore unlikely to help in identifying individuals at risk of type 1 diabetes in the general population. The OR for *CTLA-4* association with type 1 diabetes is normally not greater than 1.5 ([@B2],[@B27]). In this study, the decreased HR for progression from islet autoimmunity to type 1 diabetes with allele G (normally associated with risk) is likely a spurious finding. Overall, *CTLA-4* appears to be a stronger determinant of Graves\' disease than of type 1 diabetes ([@B27]).

In conclusion, the *PTPN22* gene seems to have a large influence on the development of early islet autoimmunity associated with early progression to type 1 diabetes and may be useful in disease prediction using genetic markers. With more accurate prediction, intervention can be provided for individuals at greatest risk.
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